Medically reviewed by Dr. Jyoti Rao, Consultant, Medical Affairs | Last reviewed July 2026
Key Takeaways
- Real-world evidence provides additional context for interpreting treatment outcomes because routine care is more heterogeneous than clinical trial populations.
- Older patients, later diagnosis, and fragmented follow-up all influence treatment outcomes.
- Persistence is among the most important real-world determinants of observed outcomes of apparent benefit.
- Real-world data clarify where differences in healthcare delivery may influence observed outcomes; they don't settle efficacy alone.
What Real-World Evidence Adds in ATTR-CM
Real-world evidence provides information on patient populations that are underrepresented in clinical trials. Routine care populations are older, carry more comorbidity, are diagnosed later in the disease, and are followed less uniformly than enrolled cohorts, so any observed treatment outcomes are influenced by access, persistence, and variability in healthcare delivery. That is the strength and limitation at once: it describes the patients encountered in routine clinical practice, but it does so without the control a trial imposes.
Why Persistence Is the Dominant Real-World Modifier
Treatment persistence is an important consideration in routine clinical practice because delayed treatment initiation, interruptions in therapy, and inconsistent follow-up may influence observed clinical outcomes. As a result, real-world studies should be interpreted in the context of treatment adherence, patient characteristics, and healthcare delivery in addition to the underlying disease process.
What Real-World Evidence Distorts Most Relative to Trials
What real-world evidence influences most is the apparent timing and magnitude of benefit because later diagnosis and incomplete follow-up result in delayed treatment initiation and changes in how clinical outcomes are assessed. Structured longitudinal monitoring narrows that distortion, but where follow-up is irregular, clinicians can attribute differences in outcomes to treatment rather than to variations in healthcare delivery as treatment effects. Accordingly, real-world findings should be interpreted cautiously; real-world data identify factors that may influence treatment outcomes in routine clinical practice, rather than establishing treatment efficacy on their own.
Frequently Asked Questions
Does real-world evidence give higher-quality evidence than trials?
No. It gives a more representative picture of routine care, but with more confounding—older, comorbid, later-diagnosed patients, and uneven follow-up—so its findings should be interpreted in the context of potential confounding factors rather than as definitive efficacy proof.
Why is persistence so important in real-world ATTR-CM data?
Persistence matters because outcomes depend on actual exposure. Delayed start, interrupted access, and fragmented follow-up can complicate assessment of disease progression, so persistence strongly shapes treatment outcomes .
What does real-world evidence distort most?
It distorts the apparent timing and magnitude of treatment benefit, since later diagnosis and irregular monitoring change when treatment begins and how response is measured.
Related Reading
Part of the Spotlight On ATTR-CM resource center.
Related Evidence
Next Clinical Decision
See the Evidence
References:
- Baseline characteristics and secondary medication adherence among Medicare patients diagnosed with ATTR-CM and/or receiving tafamidis prescriptions. Journal of Managed Care & Specialty Pharmacy
- Best Practices in Specialized Amyloidosis Centers in the United States. Clinical Medicine Insights: Cardiology
- Real-World Clinical Evidence With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy - A Contemporary Review. Circulation Reports
- Expert consensus on the monitoring of transthyretin amyloid cardiomyopathy. European Journal of Heart Failure
This content is intended for healthcare professionals for educational purposes and is not a substitute for individual clinical judgment. It was developed with AI assistance and reviewed by a qualified healthcare professional for clinical accuracy prior to publication.